NICE has published an Technology Appraisal (TA1143). This recommends fezolinetant (▼Veoza®) as an option to treat moderate to severe vasomotor symptoms associated with menopause when hormone replacement therapy (HRT) is unsuitable.

The ICB is working with system partners to implement the NICE recommendations to make fezolinetant available to women suitable for treatment. 

Primary care prescribers are requested not to prescribe fezolinetant until local implementation is complete and further guidance is issued.

Further information is available on the NICE website including news and  information for the public.